Gene profiling and resistance to Herceptin
 

http://medicineworld.org/images/blog...tion-thumb.jpgUsing gene chips to profile tumors before therapy, scientists at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary therapy for HER2-positive breast cancer. They say this advance could help further refine treatment for the 25 to 30 percent of patients with breast cancer with this class of tumor........

More...